Oppenheimer Asset Management Inc. Sells 1,110 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Oppenheimer Asset Management Inc. lessened its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 2.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,351 shares of the company's stock after selling 1,110 shares during the period. Oppenheimer Asset Management Inc. owned 0.13% of Medpace worth $11,685,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of MEDP. Lindbrook Capital LLC increased its stake in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares during the period. HBK Sorce Advisory LLC boosted its stake in shares of Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock valued at $1,789,000 after purchasing an additional 29 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares during the last quarter. Proficio Capital Partners LLC grew its position in shares of Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after buying an additional 29 shares during the period. Finally, Schulhoff & Co. Inc. raised its stake in shares of Medpace by 1.2% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock worth $874,000 after buying an additional 30 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Medpace Price Performance

NASDAQ:MEDP traded up $3.89 on Friday, hitting $310.69. 677,982 shares of the company's stock were exchanged, compared to its average volume of 372,945. The firm has a 50-day moving average price of $300.65 and a 200-day moving average price of $320.45. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $459.77. The company has a market cap of $8.93 billion, a P/E ratio of 23.72, a price-to-earnings-growth ratio of 5.61 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. Medpace had a return on equity of 54.36% and a net margin of 19.31%. The business had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. During the same quarter in the previous year, the business earned $3.20 earnings per share. On average, research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on MEDP shares. Truist Financial lowered their target price on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday, April 23rd. Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and cut their price objective for the company from $370.00 to $328.00 in a report on Monday, April 14th. Mizuho reduced their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Finally, Barclays started coverage on shares of Medpace in a research note on Tuesday. They issued an "equal weight" rating and a $300.00 target price for the company. Twelve research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $344.82.

Insider Activity at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director now owns 2,998 shares of the company's stock, valued at $904,856.36. This trade represents a 36.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 20.30% of the stock is owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.